SAGE - These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results | Benzinga
Sage Therapeutics, Inc. (NASDAQ: SAGE) reported better-than-expected fourth-quarter revenue results on Wednesday.
Sage Therapeutics posted a quarterly loss of 55 cents per share. The company’s quarterly sales came in at $77.97 million compared to market estimates of $60.98 million, according to data from Benzinga Pro.
"2023 was a pivotal year for Sage, with key accomplishments achieved across our pipeline, culminating with the recent encouraging launch of ZURZUVAE, the first-and-only once daily oral treatment for adults with postpartum depression. We are incredibly pleased with the early progress on ...